Related Experiment Video

Updated: Jul 9, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Recent advances in nonsurgical management of localized prostate cancer

Yoichi Arai1

  • 1Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. yarai@uro.med.tohoku.ac.jp

International Journal of Clinical Oncology
|December 12, 2007
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Related Experiment Videos

Last Updated: Jul 9, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial.

The Lancet. Oncology·2026

Clinicopathological Characteristics and Clinical Course of Non-muscle-invasive Bladder Cancer Secondary to Radical Nephroureterectomy.

Anticancer research·2026

Adverse Events in Testicular Cancer Survivors Using EORTC QLQ-TC26: A Multi-Institutional, Cross-Sectional Study in Japan.

International journal of urology : official journal of the Japanese Urological Association·2025

Comorbidities in Japanese testicular cancer survivors: A multi-institutional, cross-sectional study.

International journal of urology : official journal of the Japanese Urological Association·2024

Assessment of Clinicopathological Characteristics and Clinical Outcomes of Patients Who Developed Non-Muscle-Invasive Bladder Cancer After Radiotherapy for Prostate Cancer: A Retrospective Multicenter Study.

The Tohoku journal of experimental medicine·2024

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.

Nature communications·2023

From cell counts to cellular interactions: Cu-Cyto and the co-localization index as a spatial framework for the tumor immune microenvironment of rectal cancer.

International journal of clinical oncology·2026

The surrogacy of disease-free survival for overall survival in locally advanced esophageal squamous cell carcinoma after neoadjuvant therapy.

International journal of clinical oncology·2026

A multicenter retrospective study on the clinical features of patients with human epidermal growth factor receptor 2-positive colorectal cancer (HGCSG2304).

International journal of clinical oncology·2026

Gastrointestinal perforation associated with bevacizumab and palliative radiotherapy.

International journal of clinical oncology·2026

Prophylactic intravenous dexamethasone is associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma: a multicenter prospective cohort study.

International journal of clinical oncology·2026

Cost-utility analysis of CAR-T therapy compared to standard of care in patients with relapsed/refractory diffuse large B-cell lymphoma in Colombia, 2025.

International journal of clinical oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us